Anykščių medis - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 44,489 | 113,767 | 70,334 | 45,893 | 182,796 | 194,399 | 222,059 | 366,760 |
| Profit before tax | - | - | - | - | - | - | 10,341 | 7,476 |
| Net profit | 868 | 18,406 | -8,921 | 1,389 | 39,051 | 7,203 | 9,808 | 6,080 |
| Equity | 3,079 | 21,485 | 12,564 | 13,953 | 53,004 | 60,207 | 70,015 | 76,095 |
| Liabilities | 5,532 | 1,549 | 4,135 | 854 | 3,425 | 16,803 | 8,869 | 3,197 |
| Non-current assets | 1,202 | 664 | 664 | 487 | 332 | 221 | 2,333 | 3,254 |
| Current assets | 7,409 | 22,370 | 16,035 | 14,320 | 56,097 | 76,789 | 76,551 | 76,038 |
| Total assets | 8,611 | 23,034 | 16,699 | 14,807 | 56,429 | 77,010 | 78,884 | 79,292 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | - | 3,727 | - |
| Social insurance contributions | - | - | - | - | - | 3,195 | 4,928 | 10,203 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +274.1% | +155.7% | -38.2% | -34.7% | +298.3% | +6.3% | +14.2% | +65.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 10.1% | 79.9% | -53.4% | 9.4% | 69.2% | 9.4% | 12.4% | 7.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 28.2% | 85.7% | -71.0% | 10.0% | 73.7% | 12.0% | 14.0% | 8.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 2.0% | 16.2% | -12.7% | 3.0% | 21.4% | 3.7% | 4.4% | 1.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | 4.7% | 2.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.8 | 0.1 | 0.3 | 0.1 | 0.1 | 0.3 | 0.1 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 11,606 | 20,685 | 14,067 | 7,649 | 33,747 | 27,771 | 28,049 | 40,751 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Anykščių medis - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-05-16 | 2025-05-29 | 10.31 |
| 2025-05-04 | 2025-05-14 | 11.16 |
| 2025-05-01 | 2025-05-01 | 11.16 |
| 2025-04-30 | 2025-04-30 | 11.11 |
| 2025-04-24 | 2025-04-29 | 11.16 |
| 2025-04-16 | 2025-04-23 | 11.11 |
| 2025-01-22 | 2025-02-16 | 0.51 |
| 2024-12-22 | 2024-12-29 | 189.31 |
| 2024-12-17 | 2024-12-20 | 189.31 |
| 2024-11-18 | 2024-11-21 | 162.40 |
| 2024-05-16 | 2024-05-16 | 425.28 |
| 2023-04-25 | 2023-04-25 | 8.05 |
| 2023-04-20 | 2023-04-24 | 179.79 |
| 2022-11-21 | 2022-11-28 | 125.21 |
| 2022-11-17 | 2022-11-18 | 125.21 |
| 2022-10-28 | 2022-11-06 | 66.95 |
| 2022-10-18 | 2022-10-27 | 66.90 |
| 2022-01-18 | 2022-01-20 | 41.82 |
| 2021-11-16 | 2021-11-18 | 94.80 |
| 2021-10-18 | 2021-10-18 | 124.33 |
Anykščių medis - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Anykšciu medis, UAB (code 154204242) is a Private Limited Liability Company engaged in architectural activities. In 2025, the company generated €366.8K in revenue, up 65.2% year on year and 88.7% over two years. Net profit amounted to €6.1K, which implies a profit margin of 1.7%, lower than in 2024, when revenue reached €222.1K and net profit €9.8K. In 2023, revenue was €194.4K and net profit €7.2K, showing a clear upward revenue trajectory with more moderate profit development. The balance sheet remained compact in 2025, with total assets of €79.3K, equity of €76.1K, and liabilities of €3.2K. The company was highly equity-funded, with an equity ratio of 96.0% and debt-to-equity of 0.04. Asset turnover was strong at 4.63x, supported by revenue per employee of €40.8K and profit per employee of €676. Return metrics were positive, with ROE at 8.0% and ROA at 7.7% in 2025.